Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/107799
Título: | Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges | Autor: | Viana, Sofia D. Reis, Flávio Alves, Rui |
Data: | 2018 | Editora: | Hindawi | Projeto: | The authors thank HealthyAging 2020 (Centro-01-0145- FEDER-000012) for the Sofia D. Viana post-doc grant (HealthyAging2020 – BID 1.3). This work was financed by the European Regional Development Fund (ERDF) through the Centro 2020 Regional Operational Programme: project CENTRO-01-0145-FEDER-000012-HealthyAging2020 and the COMPETE 2020 - Operational Programme for Competitiveness and Internationalisation and the Portuguese national funds via Fundação para a Ciência e a Tecnologia (FCT), I.P.: project POCI-01-0145-FEDER-007440, as well as by UID/NEU/04539/2013 (CNC.IBILI Consortium strategic project) and POCI-01-0145-FEDER-031712 (project 031712). | Título da revista, periódico, livro ou evento: | Oxidative Medicine and Cellular Longevity | Volume: | 2018 | Resumo: | The mammalian (or mechanistic) target of rapamycin (mTOR) pathway has a key role in the regulation of a variety of biological processes pivotal for cellular life, aging, and death. Impaired activity of mTOR complexes (mTORC1/mTORC2), particularly mTORC1 overactivation, has been implicated in a plethora of age-related disorders, including human renal diseases. Since the discovery of rapamycin (or sirolimus), more than four decades ago, advances in our understanding of how mTOR participates in renal physiological and pathological mechanisms have grown exponentially, due to both preclinical studies in animal models with genetic modification of some mTOR components as well as due to evidence coming from the clinical experience. The main clinical indication of rapamycin is as immunosuppressive therapy for the prevention of allograft rejection, namely, in renal transplantation. However, considering the central participation of mTOR in the pathogenesis of other renal disorders, the use of rapamycin and its analogs meanwhile developed (rapalogues) everolimus and temsirolimus has been viewed as a promising pharmacological strategy. This article critically reviews the use of mTOR inhibitors in renal diseases. Firstly, we briefly overview the mTOR components and signaling as well as the pharmacological armamentarium targeting the mTOR pathway currently available or in the research and development stages. Thereafter, we revisit the mTOR pathway in renal physiology to conclude with the advances, drawbacks, and challenges regarding the use of mTOR inhibitors, in a translational perspective, in four classes of renal diseases: kidney transplantation, polycystic kidney diseases, renal carcinomas, and diabetic nephropathy. | URI: | https://hdl.handle.net/10316/107799 | ISSN: | 1942-0900 1942-0994 |
DOI: | 10.1155/2018/3693625 | Direitos: | openAccess |
Aparece nas coleções: | FMUC Medicina - Artigos em Revistas Internacionais I&D CIBB - Artigos em Revistas Internacionais I&D ICBR - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Therapeutic-use-of-mTOR-inhibitors-in-renal-diseases-Advances-drawbacks-and-challengesOxidative-Medicine-and-Cellular-Longevity.pdf | 4.26 MB | Adobe PDF | Ver/Abrir |
Citações SCOPUSTM
35
Visto em 20/mai/2024
Citações WEB OF SCIENCETM
30
Visto em 2/mai/2024
Visualizações de página
72
Visto em 15/mai/2024
Downloads
40
Visto em 15/mai/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Este registo está protegido por Licença Creative Commons